Evidence-based use of medications in patients with coronary artery disease in a rural Australian community

Australian Journal of Rural Health

Volumn 15, Issue 4, 2007, Pages 241-246

  Granmyr, Jenny ^a   Ball, Patrick ^b   Curran, Shane ^c   Wang, Lexin ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b CHARLES STURT UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Angiotensin converting enzyme inhibitor; Aspirin; Beta blocker; Drug interaction; Statin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CIPROFLOXACIN; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RANITIDINE; SHORT ACTING DRUG; SPIRONOLACTONE; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; COMMUNITY CARE; CORONARY ARTERY DISEASE; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; GLAUCOMA; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RURAL AREA; SINUS BRADYCARDIA; TEACHING HOSPITAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOTONIC AGENTS; CARDIOVASCULAR AGENTS; CORONARY ARTERIOSCLEROSIS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALS, RURAL; HOSPITALS, TEACHING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEW SOUTH WALES; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RURAL HEALTH SERVICES;

EID: 34447315260     PISSN: 10385282     EISSN: 14401584     Source Type: Journal    
DOI: 10.1111/j.1440-1584.2007.00902.x     Document Type: Article

References (27)

1. Australian Institute of Health and Welfare (AIHW). Heart, Stroke and Vascular Diseases - Australian Facts, AIHW Cat No CVD 27. Canberra: AIHW, 2004.
2. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Guidelines for the management of acute coronary syndromes 2006. Medical Journal of Australia 2006; 184: 23.
3. Antithrombotic Trialist' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death. Myocardial infarction, and stroke in high risk patients. British Medical Journal 2002; 324: 71-86.
4. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Progress in Cardiovascular Disease 1985; 27: 335-371.
5. Norwegian Multicentre Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine 1981; 304: 801-807.
6. Anonymous. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality result. Journal of the American Medical Association 1982; 247: 1707-1714.
7. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β-Blockade after myocardial infarction: Systemic review and meta regression analysis. British Medical Journal 1999; 318: 1730-1737.
8. The HOPE Investigators. Effects of on angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine 2000; 342: 145-153.
9. Fox KM and European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, muticentre trial (the EUROPA study). Lancet 2003; 362: 782-777.
10. Dagenais G, Pogue J, Fox K, Simoons M, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Lancets 2006; 368: 581-588.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
12. Sacks F, Pfeffer M, Moye L et al. for the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996; 335: 1001-1009.
13. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990-2002. Journal of the American College of Cardiology 2003; 41: 56-61.
14. Krumholtz H, Radford M, Wang Y, Chen J, Heiat A, Marciniak T. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. Journal of American Medical Association 1998; 280: 623-629.
15. Barron H, Michaels A, Maynard C, Every N for the National Registry of Myocardial Infarction 2 Participants. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2. Journal of the American College of Cardiology 1998; 32: 360-367.
16. Schwiesow SJ, Nappi JM, Raqucci KR. Assessment of compliance with lipid guidelines in an academic medical center. Annals of Pharmacotherapy 2006; 40: 27-31.
17. Sueta C, Massing M, Chowdhury M, Biggs D, Simpson R. Undertreatment of hyperlipidemia in patients with Coronary Artery Disease and Heart Failure. Journal of Cardiac Failure 2003; 9: 36-41.
18. Läkemedelsindustriförening LIF. FASS 2006. [Cited Nov 2006]. Available from URL: http://www.fass.se/LIF/home/index.jsp?UserTypeID=0
19. Hypertension Management Guide for Doctors. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. [Cited Aug 2006]. Available from URL: http://www.heartfoundation.com.au/downloads/ hypertension_management_guide_2004.pdf
20. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease, Reviews. Cochrane Database Systemic Review 2005; 19: CD003566.
21. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL on behalf of the CHF Guidelines Core Writers. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Medical Journal of Australia 2006; 185: 549-556.
22. Shlipak M. Pharmacotherapy for heart failure in patients with renal insufficiency. Annals of International Medicine 2003; 138: 917-924.
23. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
24. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 580 50 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
25. Kvan E, Pettersen KI, Landmark K, Reikvam A, INPHARM Study Investigators. Treatment with statins after acute myocardial infarction in patients ≥80years: Underuse despite general acceptance of drug therapy for secondary prevention. Pharmacoepidemiology and Drug Safety 2006; 15: 261-267.
26. Wolff AM, Taylor SA, McCabe JF. Using checklists and reminders in clinical pathways to improve hospital inpatient care. Medical Journal of Australia 2004; 181: 428-431.
27. Holbrook A, Pereira J, Labiris R et al. Systemic overview of warfarin and its drug and food interaction. Archives of International Medicine 2005; 165: 1095-1106.